Immunosuppressive drug-induced diabetes

Penfornis, A.; Kury-Paulin, S

doi:10.1016/s1262-3636(06)72809-9

Cited by 129 publications

(97 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The efficacy of various glucocorticoid-sparing regimens has been examined in organ transplantation. 43 PTDM increases the risk of mortality after solid organ transplantation. 44 Using large databases, Hayer et al 45 reported that pretransplant DM was associated with an increased risk of overall and specifically infection-related mortality after kidney transplantation.…”

Section: Ptdm and Clinical Outcomesmentioning

confidence: 99%

How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT

Fuji

Rovó

Ohashi

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients frequently develop glucose intolerance and post-transplant diabetes mellitus (PTDM). The clinical importance of PTDM and its detrimental impact on HSCT outcomes are underrecognized. After allo-HSCT, various mechanisms can contribute to the development of PTDM. Here we review information about hyperglycemia and PTDM after allo-HSCT as well as PTDM after solid organ transplantation and describe ways to manage hyperglycemia/PTDM after allogeneic HSCT. Taking into consideration a lack of well-established evidence in the field of allo-HSCT, more studies should be conducted in the future, which will require closer multidisciplinary collaboration between hematologists, endocrinologists and nutritionists.

show abstract

Section: Ptdm and Clinical Outcomesmentioning

confidence: 99%

How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT

Fuji

Rovó

Ohashi

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Risk of NODAT increases with Tac trough concentrations >15 ng/mL during the first month after transplantation [84]. Tac's profound diabetogenic effect may be due to Tac specific binding to FKBP-12 which is preferentially located in β-cells, resulting in Tac concentrating there [85]. CsA specifically binds to cyclophilin which is preferentially located in the heart, liver and kidneys [85].…”

Section: Calcineurin Inhibitors (Cni)mentioning

confidence: 99%

“…Tac's profound diabetogenic effect may be due to Tac specific binding to FKBP-12 which is preferentially located in β-cells, resulting in Tac concentrating there [85]. CsA specifically binds to cyclophilin which is preferentially located in the heart, liver and kidneys [85]. Reducing the target for Tac trough concentrations below 10 ng/ml,Tac dose, or switching from Tac to CsA may lower the incidence of NODAT or be effective in managing NODAT [84,86].…”

Section: Calcineurin Inhibitors (Cni)mentioning

confidence: 99%

Medications affecting glycemic control

Korayem¹

2017

Int Clin Med

View full text Add to dashboard Cite

show abstract

“…Glucocorticoids are well known for leading to hyperglycemia by increasing glucose resistance, reducing insulin secretion and inducing beta cells apoptosis; they have been shown to reduce the expression of glucose transporter 2 and glucokinase 28 . The effect of glucocorticoids is dose-dependent.…”

Section: Glucocorticoidsmentioning

confidence: 99%

New-onset diabetes mellitus after renal transplantation

Goldmannová¹,

Karásek²,

Krystynik³

et al. 2016

BIOMED PAP

View full text Add to dashboard Cite

Background and Aim. Diabetes mellitus is a very common metabolic disease with a rising incidence. It is both a leading cause of chronic renal disease and one of the most serious comorbidities in renal transplant recipients. New-onset diabetes after renal transplantation (NODAT) is associated with poor graft function, higher rates of cardiovascular complications and a poor prognosis. The aim of this paper is to review current knowledge of NODAT including risk factors, diagnosis and management. Methods. A MEDLINE search was performed to retrieve both original and review articles addressing the epidemiology, risk factors, screening and management of NODAT. We also focused on microRNAs as potential biomarkers of NODAT. Results and Conclusion. Understanding the risk factors (both modifiable-e.g. obesity, viruses, and unmodifiable-e.g. age, genetics) may help reduce the incidence and impact of NODAT using pre-and post-transplant management. This can lead to better long-term graft function and general transplant success.

show abstract

Immunosuppressive drug-induced diabetes

Cited by 129 publications

References 77 publications

How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT

How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT

Medications affecting glycemic control

New-onset diabetes mellitus after renal transplantation

Contact Info

Product

Resources

About